The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study
Abstract
OBJECTIVE: This study investigated whether treatment with the anti-tumor necrosis factor-alpha monoclonal antibody afelimomab would improve survival in septic patients with serum interleukin (IL)-6 concentrations of >1000 pg/mL. DESIGN: Multicenter, double-blind, randomized, placebo-controlled study. SETTING: Eighty-four intensive care units in academic medical centers in Europe and Israel. PATIENTS: A total of 944 septic patients were screened and stratified by the results of a rapid qualitative immunostrip test for serum IL-6 concentrations. Patients with a positive test kit result indicating IL-6 concentrations of >1000 pg/mL were randomized to receive either afelimomab (n = 224) or placebo (n = 222). Patients with a negative IL-6 test (n = 498) were not randomized and were followed up for 28 days. INTERVENTIONS: Treatment consisted of 15-min infusions of 1 mg/kg afelimomab or matching placebo every 8 hrs for 3 days. Standard surgical and intensive care therapy was otherwise delivered. MEASUREMENTS AND MAIN RESULTS: The study was terminated prematurely after an interim analysis estimated that the primary efficacy end points would not be met. The 28-day mortality rate in the nonrandomized patients (39.6%, 197 of 498) was significantly lower (p <.001) than that found in the randomized patients (55.8%, 249 of 446). The mortality rates in the IL-6 test kit positive patients randomized to afelimomab and placebo were similar, 54.0% (121 of 224) vs. 57.7% (128 of 222), respectively. Treatment with afelimomab was not associated with any particular adverse events. CONCLUSIONS: The IL-6 immunostrip test identified two distinct sepsis populations with significantly different mortality rates. A small (3.7%) absolute reduction in mortality rate was found in the afelimomab-treated patients. The treatment difference did not reach statistical significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Self-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Shock and Tissue Injury Induced by Recombinant Human Cachectin
Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey, T. J., Zentella, A., Albert, J. D., et al. (1986) · Science · doi:10.1126/science.3764421 · Cited by 2,549
Multiple Organ Dysfunction Score: A reliable descriptor of a complex clinical outcome
Marshall, J. C., Cook, D. J., Christou, N. V., Bernard, G. R., Sprung, C. L., & Sibbald, W. J. (1995) · Critical Care Medicine · doi:10.1097/00003246-199510000-00007 · Cited by 2,532
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
Fisher, C. J., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E., Schein, R. M. H., & Benjamin, E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342603 · Cited by 1,241
Schindler, R., Mancilla, J., Endres, S., Ghorbani, R., Clark, S., & Dinarello, C. (1990) · Blood · doi:10.1182/blood.v75.1.40.40 · Cited by 1,012
Tilg, H., Trehu, E., Atkins, M., Dinarello, C., & Mier, J. (1994) · Blood · doi:10.1182/blood.v83.1.113.113 · Cited by 817
Cytokine Serum Level During Severe Sepsis in Human IL-6 as a Marker of Severity
DAMA, P., LEDOUX, D., NYS, M., VRINDTS, Y., GROOTE, D. D., FRANCHIMONT, P., & LAMY, M. (1992) · Annals of Surgery · doi:10.1097/00000658-199204000-00009 · Cited by 808
Abraham, E. (1998) · The Lancet · doi:10.1016/s0140-6736(00)80009-4 · Cited by 624
Cited by
Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome
Bhatia, M., & Moochhala, S. (2004) · The Journal of Pathology · doi:10.1002/path.1491 · Cited by 1,095
Sepsis: a roadmap for future research
Cohen, J., Vincent, J.-L., Adhikari, N. K. J., Machado, F. R., Angus, D. C., Calandra, T., Jaton, K., Giulieri, S., Delaloye, J., Opal, S., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70112-x · Cited by 992
Self-citationNew Approaches to Sepsis: Molecular Diagnostics and Biomarkers
Reinhart, K., Bauer, M., Riedemann, N. C., & Hartog, C. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00016-12 · Cited by 533
Self-citationA randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*
Rice, T. W., Wheeler, A. P., Bernard, G. R., Vincent, J.-L., Angus, D. C., Aikawa, N., Demeyer, I., Sainati, S., Amlot, N., Cao, C., et al. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e7c5c9 · Cited by 512
Self-citationRemick, D. G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060872 · Cited by 501
Metadata
- Authors
- Reinhart, K., Menges, T., Gardlund, B., Harm Zwaveling, J., Smithes, M., Vincent, J.-L., Maria Tellado, J., Salgado-Remigio, A., Zimlichman, R., Withington, S., Tschaikowsky, K., Brase, R., Damas, P., Kupper, H., Kempeni, J., Eiselstein, J., & Kaul, M.
- Venue
- Critical Care Medicine
- Published
- 2001-04
- Volume
- 29
- Issue
- 4
- Pages
- 765-769
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2124925985
- Cited by
- 257
- References
- 21
- FWCI
- 18.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. https://app.cochat.ai/papers/10.1097/00003246-200104000-00015
- The paper
- Reinhart, K., Menges, T., Gardlund, B., Harm Zwaveling, J., Smithes, M., Vincent, J.-L., Maria Tellado, J., Salgado-Remigio, A., Zimlichman, R., Withington, S., Tschaikowsky, K., Brase, R., Damas, P., Kupper, H., Kempeni, J., Eiselstein, J., & Kaul, M. (2001). Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Critical Care Medicine. https://doi.org/10.1097/00003246-200104000-00015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.